Cellectis (CLLS) Capital Expenditures Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 46.88% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 8.97% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 16.27% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -7.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.55% |
| Dec 31, 2025 | -24.78% |
| Sep 30, 2025 | -38.14% |
| Jun 30, 2025 | 30.66% |
| Mar 31, 2025 | 14.23% |
| Dec 31, 2024 | -49.94% |
| Sep 30, 2024 | 44.77% |
| Jun 30, 2024 | 42.46% |
| Mar 31, 2024 | 70.14% |
| Dec 31, 2023 | -77.74% |
| Sep 30, 2023 | 63.27% |
| Jun 30, 2023 | 73.17% |
| Mar 31, 2023 | 70.03% |
| Dec 31, 2022 | -42.45% |
| Sep 30, 2022 | 56.56% |
| Jun 30, 2022 | 32.68% |
| Mar 31, 2022 | 29.83% |
| Dec 31, 2021 | 72.78% |
| Sep 30, 2021 | -55.24% |
| Jun 30, 2021 | -114.66% |
| Mar 31, 2021 | -134.52% |
| Dec 31, 2020 | 157.19% |
| Sep 30, 2020 | -121.11% |
| Jun 30, 2020 | -140.49% |
| Mar 31, 2020 | -143.80% |
| Dec 31, 2019 | -4.06% |
| Sep 30, 2019 | -30.14% |
| Jun 30, 2019 | -3.28% |
| Mar 31, 2019 | 37.18% |
| Dec 31, 2018 | 137.16% |
| Sep 30, 2018 | -84.68% |
| Jun 30, 2018 | -8.07% |
| Mar 31, 2018 | 41.06% |